Clinical Trials Logo

Brain Neoplasms clinical trials

View clinical trials related to Brain Neoplasms.

Filter by:

NCT ID: NCT03561896 Active, not recruiting - Clinical trials for Brain Metastases, Adult

Hypofractionated Brain Radiationcavity

Start date: January 2015
Phase: N/A
Study type: Interventional

Stereotactic radiosurgery or hypofractionated radiotherapy of the resection cavity after metastasectomy in cancer patients with brain metastases

NCT ID: NCT03483012 Active, not recruiting - Breast Cancer Clinical Trials

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Start date: May 1, 2018
Phase: Phase 2
Study type: Interventional

This research study is studying the combination of a drug called atezolizumab and a radiation procedure called stereotactic radiosurgery (SRS) as a possible treatment for triple-negative breast cancer that has spread to the brain. The interventions involved in this study are: - Atezolizumab - Stereotactic radiosurgery (SRS)

NCT ID: NCT03478462 Active, not recruiting - Neuroblastoma Clinical Trials

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

CLOVER-2
Start date: April 30, 2019
Phase: Phase 1
Study type: Interventional

The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.

NCT ID: NCT03465618 Active, not recruiting - Brain Cancer Clinical Trials

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

Start date: March 7, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test if PET scans using 89Zr-DFO-cRGDY-PEG-Cy5-C' dot particles, can be used to take pictures of brain tumors. The investigators want to understand how the particles are distributed and removed from the body, which may help others be treated in the future. This will be the first time that 89Zr-DFO-cRGDY-PEG-Cy5-C' dot particles are being used in people. The amount of particles given in this study is very small compared to the amount that was used in mice animal studies.

NCT ID: NCT03458455 Active, not recruiting - Brain Metastases Clinical Trials

Improved Therapy Response Assessment in Metastatic Brain Tumors

TREATMENT
Start date: March 1, 2013
Phase:
Study type: Observational [Patient Registry]

TREATMENT is an observational study addressing the need for knowledge and adequate diagnostic biomarkers in the response assessment of patients with brain metastasis. Reliable response assessment will be highly relevant in the coming years given the introduction of next-generation cancer drugs, including immunotherapy. This project uses advanced Magnetic Resonance Imaging (MRI) and Vessel Architecture Imaging (VAI) to better understand the response to traditional stereotactic radiosurgery (SRS) and immunotherapy. Secondary objectives include: In patients with brain metastases, use advanced MRI and Vessel Architectural Imaging methods to reveal parameters of traditional, immunotherapeutic, and anti-angiogenic therapy response. In patients with brain metastases, use advanced MRI and Vessel Architectural Imaging methods to compare results with traditional biomarkers. Use existing infrastructure at Oslo University Hospital to standardize therapy monitoring. In patients with brain metastases, use advanced MRI and Vessel Architectural Imaging methods to separate real tumor progression from treatment-induced pseudoprogression or radionecrosis In patients with brain metastases, use advanced MRI and Vessel Architectural Imaging methods to assess whether anti-angiogenic drugs improve delivery of chemotherapy.

NCT ID: NCT03412812 Active, not recruiting - Brain Metastases Clinical Trials

A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases

RAD1705
Start date: July 30, 2018
Phase: N/A
Study type: Interventional

This study looks at dose escalation for five fraction stereotactic radiotherapy for patients diagnosed with brain metastases with tumors 2.1-4.0 cm in diameter or 4.1-6.0 cm in diameter.

NCT ID: NCT03398694 Active, not recruiting - Brain Metastases Clinical Trials

Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients With Brain Metastases

Start date: March 26, 2018
Phase: N/A
Study type: Interventional

This is a prospective, single arm, phase II trial to determine the local control at 6 months utilizing pre-operative stereotactic radiosurgery followed by surgery within 1 - 4 days in subjects with a diagnosis of 1-4 brain metastases and with an indication for surgical resection of at least one brain metastasis at the discretion of a neurosurgeon.

NCT ID: NCT03391362 Active, not recruiting - Clinical trials for Small Cell Lung Cancer

Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases

Start date: February 23, 2018
Phase: N/A
Study type: Interventional

This research study is studying stereotactic radiation (focused/pinpoint radiation that targets each individual tumor but not the surrounding brain) instead of whole-brain radiation (radiation targeting the entire brain) as a possible treatment for patients with small cell lung cancer and 1-10 brain metastases. The intervention involved in this study is: -Stereotactic (focused, pinpoint) radiation

NCT ID: NCT03361033 Active, not recruiting - Clinical trials for Brain Tumor, Pediatric

Components of Social Functioning in Survivors of Pediatric Brain Tumors

Start date: January 30, 2018
Phase:
Study type: Observational

Children with brain tumors are at risk for a number of psychological late effects, including neurocognitive and social deficits. This observational study focuses on assessment of social functioning, including social-cognitive and neurocognitive abilities, in survivors of pediatric brain tumors. This study will also assess the influence of medical factors, including diagnosis and age at diagnosis, on social functioning. PRIMARY OBJECTIVE: Examine the impact of social-cognitive and neurocognitive abilities on social functioning in survivors of pediatric brain tumors. SECONDARY OBJECTIVE: Assess the influence of medical factors such as diagnosis and age at diagnosis on the social functioning of survivors of pediatric brain tumors.

NCT ID: NCT03346655 Active, not recruiting - Brain Metastases Clinical Trials

Brain Metastases in Norway - A Prospective Cohort Study

Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

The overall aim and primary outcome of this study will be a descriptive analysis of the current treatment practice of BM in Norway. Specifically, it may give answers to the following research questions: - What is the true incidence of BM in Norway? - How are patients with BM treated at present? - Do treatments differ between hospitals? - How do treatments impact quality of life of the patients? - Which factors (treatment, tumor and host variables) can explain disease control, survival, symptom relief, and general functions? - How can BM staging be improved?